Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease
1 clinical trials · Condition
◉ Watch Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease
| Record | Firm | Date |
|---|---|---|
| Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma (NCT07622940) | Beijing Biotech | 2026-03-02 |
Track Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease automatically
Every clearance here is in the API, with alerts when new ones post.